CrowdGather to Have Exclusive Rights to ER303 for Internet Affiliate
Marketing
WOODLAND HILLS, Calif., May 17, 2011 (BUSINESS WIRE) --
One of the leading networks of forum communities on the Internet,
CrowdGather (OTCBB: CRWG) today announced that it has acquired brand
assets from Human Pheromone Sciences, Inc. (OTCBB: EROX), a company
engaged in the research, development, manufacturing and marketing of
consumer products containing synthetic human pheromones. CrowdGather
will partner with Human Pheromone Sciences to launch and distribute
Erox(R), a unisex fragrance, which has been proven to increase feelings of
arousal, excitement, social warmth and friendliness in both female and
male users. The fragrance will be launched, sold and marketed through
the use of social media and forum communities. Erox(R) will be the first
commercial product to contain Human Pheromone Sciences' patent pending
ER303 compound which has been shown to increase feelings of attraction
and flirtiness in both males and females during a double blind placebo
controlled study.
The new venture will provide CrowdGather with the opportunity to expand
its offerings as it seeks to utilize social media in unique ways to
efficiently take products to market.
"Forums provide a platform for people to discuss and recommend products
that matter most to them," said CrowdGather CEO Sanjay Sabnani.
"Partnering with strategic partners to create exclusive products for
marketing through social media and forum communities will provide us
with greater control over our future revenue streams and also showcase
how powerful a channel this can be for launching and selling future
products."
As part of the agreement CrowdGather will acquire the Erox.com domain
name and trademarks from Human Pheromone Sciences, and make a strategic
investment in the company via a private placement at the time a final
product is accepted by CrowdGather. Human Pheromone Sciences will design
and contract out the manufacture of the fragrance for CrowdGather and
its distribution partners.
"Our company has had a long standing relationship with CrowdGather's CEO
and we are delighted to have them as a partner in bringing this product
to market via the Internet. While we have had a history of our compounds
being used in successful fragrance products, this is the first time we
are launching a new product using nontraditional channels. We are very
excited at the prospects," commented William P. Horgan, CEO of Human
Pheromone Sciences.
Human pheromones are naturally occurring substances that trigger
specific behavioral or physiological response. Erox will be the only
commercial product to contain the combination of ER303 and patented
human pheromone compounds Androstadienone and Estratetraenoll, both of
which can be found in iconic brands such as Avon's Perceive(R) ,
Victoria's Secret's Very Sexy(R), Henkel's hair care line, got2b(R), and
selected Dial Corporation body washes. Erox(R) will be the first
commercial product to contain ER303 which bears a structural similarity
to human pheromones, but is instead derived from a species of sea coral.
About CrowdGather, Inc.
With its growing portfolio of special interest forums and enthusiast
message board communities, CrowdGather (www.crowdgather.com)
has created a centralized network to benefit forum members, forum owners
and forum advertisers. CrowdGather provides a highly interactive and
informational social network for members, a management and
revenue-sharing resource for third-party forum owners, and a largely
untapped advertising network for marketers worldwide.
About Human Pheromone Sciences, Inc.
Human Pheromone Sciences, Inc. is a technology-based company, whose
proof-of concept products included prestige-priced fragrances and
toiletries and environmental products sold under the Natural
Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These
products contain mood-enhancing compounds, whose efficacy has been
validated at leading universities around the world, and whose use is
covered under United States and foreign patents.
The Company is also involved in research and product development efforts
on new compounds that have been previously identified as stimulating the
emotional centers of the human brain.
This press release contains forward-looking statements (as defined in
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended) concerning future
events and the Company's growth and business strategy.Words such
as "expects," "will," "intends," "plans," "believes," "anticipates,"
"hopes," "estimates," and variations on such words and similar
expressions are intended to identify forward-looking statements.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, no assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of
assumptions and estimates that are inherently subject to significant
uncertainties and contingencies, many of which are beyond the control of
the Company. Actual results may differ materially from those expressed
or implied by such forward-looking statements.Factors that could
cause actual results to differ materially include, but are not limited
to, changes in the Company's business; competitive factors in the
market(s) in which the Company operates; risks associated with
operations outside the United States; and other factors listed from time
to time in the Company's filings with the Securities and Exchange
Commission. The Company expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
Company's expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
SOURCE: CrowdGather, Inc.
Investor Contact - CrowdGather:
Sanjay Sabnani, 818-435-2472 x101
sanjay@crowdgather.com
or
Investor Contact - HPSI:
William P. Horgan, 408-938-3030
bill@erox.com
or
Media Contact:
Stacy Dimakakos, 917-981-5501
stacy@publicworldwide.com
